FDA clears IND application for TBS-2025 in AML
The upcoming Phase 2 study will utilize a Simon 2-stage design and focus on patients who have not previously received a menin inhibitor.
Leukemia
Acute Myeloid Leukemia
News
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves acalabrutinib plus venetoclax for CLL, SLL
The approval follows results based on the phase 3 AMPLIFY trial, which showed that this fixed-duration combination significantly improved progression-free survival compared to
ASH 2025
Acute Myeloid Leukemia
News
Prof. Charles Craddock, CBE, discusses paradigm trial, transplant advances at ASH 2025
Charles Craddock, CBE, FRCP, FRCPath, professor of hematology-oncology at the University of Birmingham and consultant hematologist at University Hospitals Birmingham, shares ASH 2025
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
News
Assay targeting KMT2A rearrangements in AML now available
Invivoscribe has announced the launch of its newly developed test for leukemia diagnostics, the LeukoStrat® KMT2A + MRD Assay, specifically for patients with
Multiple Myeloma
News
FDA issues draft guidance on MRD, CR endpoints in MM clinical trials
The FDA has released a new draft guidance focused on using minimal residual disease (MRD) and complete response (CR) as primary endpoints in
SOHO Asia 2026
Ambassador Program
News
Video Interviews
Dr. Bor-Sheng Ko discusses the future of SOHO Asia and regional collaborations
Bor-Sheng Ko, MD, PhD, Associate Professor at National Taiwan University College of Medicine and President of the Hematology Society of Taiwan, discusses the
SOHO Asia 2026
Ambassador Program
Multiple Myeloma
Myelodysplastic Syndromes
Myeloproliferative Neoplasms
News
Yu-Hung Wang, MD, PhD, discusses unmet needs in myeloid neoplasms at SOHO Asia
In this video interview from SOHO Asia, Dr. Wang, MD, PhD, consultant hematologist at National Taiwan University Cancer Center, discusses the current unmet
Cellular Therapy
Lymphoma
Aggressive B-Cell Lymphomas
News
FDA removes axi-cel limitations of use for primary CNS lymphoma
The US Food and Drug Administration (FDA) approved an update to the prescribing information for axicabtagene ciloleucel (Yescarta), removing the previous Limitations of
SOHO 2026
Leukemia
Acute Lymphoblastic Leukemia
News
SOHO Insider Podcast
Society Updates
Public-private partnerships needed to sustain progress in blood cancer treatment
John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of
Leukemia
Acute Lymphoblastic Leukemia
Lymphoma
T-Cell Lymphoma
News
FDA approves larger Nelarabine vial size for T-ALL and T-LBL
The United States Food and Drug Administration (FDA) has signed off on a new, larger vial size for Nelarabine Injection for adult and